SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
Br J Haematol
; 201(3): 411-416, 2023 05.
Article
in English
| MEDLINE | ID: covidwho-2304776
ABSTRACT
Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Leukemia
/
Leukemia, Hairy Cell
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Br J Haematol
Year:
2023
Document Type:
Article
Affiliation country:
Bjh.18606
Similar
MEDLINE
...
LILACS
LIS